Project Grant HT94252410974
Award Date
11/1/24
Completion Date
10/31/27
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This $1,555,176 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) will support the University of Michigan's research on therapeutic modulation of the serine/threonine phosphatase PP2A for the treatment of uterine serous cancer (USC) and uterine carcinosarcoma (UCS). The award, which runs from Aug 2024 to Aug 2027, will enable the University to conduct advanced biomedical research aimed at transforming...
This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
This Project Grant award of $546,000.00 from the Defense Health Agency supports research at the Regents of the University of Michigan to develop a novel lectin for targeting T-cell lymphomas. The award is part of the Military Medical Research and Development program (CFDA 12.420), which funds basic, applied, and advanced biomedical research to transform healthcare for service members and the public through innovative and impactful research. The 3-year award began on September 1, 2023 and will...
The Defense Health Agency awarded a $607,377 Project Grant to the Regents of the University of Michigan to fund a 2-year research project titled "A NEW IDEA FOR ADVANCING AXITINIB-BASED THERAPY IN RECURRENT AND METASTATIC HNSCC." This grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for service members and the public. The University of Michigan, a leading...
The Defense Health Agency awarded a $1,178,939.00 Project Grant to the Regents of the University of Michigan under the Military Medical Research and Development program (CFDA 12.420) to conduct advanced phenotyping research to improve diagnostic, longitudinal assessment, and treatment strategies for deployment-related respiratory disease. The award period is from September 1, 2023 to August 31, 2026. As a U.S. Government Entity and top public research university, the University of Michigan has...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
This federal Project Grant award, valued at $705,263.00 and effective from September 30, 2024 to September 29, 2027, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research at Northwestern University's Sponsored Research Division to conduct single-cell tracking of the transformation of lung adenocarcinoma to small cell lung cancer. This cutting-edge research aims to advance the scientific understanding of lung...
The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
The University of Michigan will receive $1.2 million from the Defense Health Agency under a three-year Project Grant award for research titled "FADD: A Mechanistic Basis and Therapeutic Opportunity for Overcoming CDK4/6 Inhibitor Resistance." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for...
This federal Project Grant award for $1,518,817.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is for research to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The award was made to the Weill Medical College of Cornell University, a prestigious academic medical institution with extensive experience conducting biomedical research for federal agencies. The project aims to...